107 related articles for article (PubMed ID: 30663569)
1. Effect of Early Normotension with Olmesartan on Rho-kinase Activity in Hypertensive Patients.
Cantin C; Jalil JE; Bulnes JF; Novoa U; MacNab P; Godoy I; Córdova S; Gabrielli L; Ocaranza MP
Curr Vasc Pharmacol; 2020; 18(1):87-91. PubMed ID: 30663569
[TBL] [Abstract][Full Text] [Related]
2. The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling.
Ravarotto V; Pagnin E; Maiolino G; Fragasso A; Carraro G; Rossi B; Calò LA
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1245-50. PubMed ID: 26240115
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
4. Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.
Koc Y; Mazi E; Sakaci T; Basturk T; Damar AB; Ahbap E; Unsal A; Borlu F
Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1389-94. PubMed ID: 22288300
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Rosenbaum D; Girerd X
Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
[TBL] [Abstract][Full Text] [Related]
6. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
Ewald S; vor dem Esche J; Uen S; Neikes F; Vetter H; Mengden T
Clin Drug Investig; 2006; 26(8):439-46. PubMed ID: 17163276
[TBL] [Abstract][Full Text] [Related]
8. WIN OVER study: Efficacy and safety of olmesartan in Indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational study.
Kumbla DK; Kumar S; Reddy YV; Trailokya A; Naik M
Indian Heart J; 2014; 66(3):340-4. PubMed ID: 24973841
[TBL] [Abstract][Full Text] [Related]
9. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
Cal LA; Maso LD; Caielli P; Pagnin E; Fusaro M; Davis PA; Pessina AC
Blood Press; 2011 Dec; 20(6):376-82. PubMed ID: 21504378
[TBL] [Abstract][Full Text] [Related]
10. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
Zannad F; Fay R
Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
[TBL] [Abstract][Full Text] [Related]
12. Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.
Fogari R; Zoppi A; Mugellini A; Preti P; Perrone T; Maffioli P; Derosa G
Expert Opin Pharmacother; 2012 Apr; 13(5):629-36. PubMed ID: 22372508
[TBL] [Abstract][Full Text] [Related]
13. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Mallion JM; Heagerty A; Laeis P
J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension.
Shiga Y; Miura SI; Motozato K; Norimatsu K; Yano M; Hitaka Y; Adachi S; Kuwano T; Inoue K; Inoue A; Fujisawa K; Shirotani T; Kusumoto T; Ideishi M; Saku K
Int Heart J; 2017 May; 58(3):416-421. PubMed ID: 28496022
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
Punzi HA
Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
[TBL] [Abstract][Full Text] [Related]
16. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
[TBL] [Abstract][Full Text] [Related]
17. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
Neutel JM; Kereiakes DJ; Waverczak WF; Stoakes KA; Xu J; Shojaee A
Curr Med Res Opin; 2010 Mar; 26(3):721-8. PubMed ID: 20085534
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study).
Jung HW; Kim KI; Park CG; Kang DH; Ahn Y; Bae JH; Kim CH
Clin Exp Hypertens; 2015; 37(6):482-9. PubMed ID: 25816197
[TBL] [Abstract][Full Text] [Related]
19. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.
Sellin L; Stegbauer J; Laeis P; Rump LC
J Hypertens; 2005 Nov; 23(11):2083-92. PubMed ID: 16208152
[TBL] [Abstract][Full Text] [Related]
20. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.
Stumpe KO; Agabiti-Rosei E; Zielinski T; Schremmer D; Scholze J; Laeis P; Schwandt P; Ludwig M;
Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):97-106. PubMed ID: 19124398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
